AU4156197A - Oligonucleotide prodrugs - Google Patents
Oligonucleotide prodrugsInfo
- Publication number
- AU4156197A AU4156197A AU41561/97A AU4156197A AU4156197A AU 4156197 A AU4156197 A AU 4156197A AU 41561/97 A AU41561/97 A AU 41561/97A AU 4156197 A AU4156197 A AU 4156197A AU 4156197 A AU4156197 A AU 4156197A
- Authority
- AU
- Australia
- Prior art keywords
- oligonucleotide prodrugs
- prodrugs
- oligonucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108091034117 Oligonucleotide Proteins 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2426296P | 1996-08-21 | 1996-08-21 | |
US60024262 | 1996-08-21 | ||
PCT/US1997/014751 WO1998007734A1 (en) | 1996-08-21 | 1997-08-21 | Oligonucleotide prodrugs |
Publications (1)
Publication Number | Publication Date |
---|---|
AU4156197A true AU4156197A (en) | 1998-03-06 |
Family
ID=21819691
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU41561/97A Abandoned AU4156197A (en) | 1996-08-21 | 1997-08-21 | Oligonucleotide prodrugs |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU4156197A (en) |
WO (1) | WO1998007734A1 (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR030558A1 (en) | 2000-04-19 | 2003-08-27 | Schering Corp | MACROCICLIC COMPOUNDS, WHICH INCLUDE ENANTIOMERS, STEROISOMERS, ROTAMERS AND TAUTOMEROS, SALTS AND PHARMACEUTICALLY ACCEPTABLE SOLVATOS, PHARMACEUTICAL COMPOSITION, A METHOD FOR THE PREPARATION AND THE USE OF SUCH COMPUTERS FOR THE INHIBITION, THE SERIES |
DE60141608D1 (en) | 2000-07-21 | 2010-04-29 | Dendreon Corp | PEPTIDES AS INHIBITORS OF THE NS3 SERINE PROTEASE OF HEPATITIS C VIRUS |
US6911428B2 (en) | 2000-12-12 | 2005-06-28 | Schering Corporation | Diaryl peptides as NS3-serine protease inhibitors of hepatitis C virus |
EP1487851A2 (en) * | 2002-03-15 | 2004-12-22 | Nuevolution A/S | A building block capable of functional entity transfer to nucleophil |
WO2006065751A2 (en) * | 2004-12-13 | 2006-06-22 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Cpg oligonucleotide prodrugs, compositions thereof and associated therapeutic methods |
US8076303B2 (en) | 2005-12-13 | 2011-12-13 | Spring Bank Pharmaceuticals, Inc. | Nucleotide and oligonucleotide prodrugs |
CN102123716B (en) | 2008-04-03 | 2013-09-18 | 春堤公司 | Compositions and methods for treating viral infections |
ES2616051T3 (en) | 2008-12-02 | 2017-06-09 | Wave Life Sciences Japan, Inc. | Method for the synthesis of modified nucleic acids in the phosphorus atom |
CA2747999A1 (en) * | 2008-12-23 | 2010-07-01 | Girindus America, Inc. | Sulfurizing reagents and their use for oligonucleotides synthesis |
US9744183B2 (en) * | 2009-07-06 | 2017-08-29 | Wave Life Sciences Ltd. | Nucleic acid prodrugs and methods of use thereof |
EP2620428B1 (en) | 2010-09-24 | 2019-05-22 | Wave Life Sciences Ltd. | Asymmetric auxiliary group |
KR20140068884A (en) | 2011-07-19 | 2014-06-09 | 웨이브 라이프 사이언시스 피티이. 리미티드 | Methods for the synthesis of functionalized nucleic acids |
JP6268157B2 (en) | 2012-07-13 | 2018-01-24 | 株式会社Wave Life Sciences Japan | Asymmetric auxiliary group |
CN112007045A (en) | 2012-07-13 | 2020-12-01 | 波涛生命科学有限公司 | Chiral control |
MX356830B (en) | 2012-07-13 | 2018-06-15 | Shin Nippon Biomedical Laboratories Ltd | Chiral nucleic acid adjuvant. |
IN2015DN01765A (en) | 2012-08-20 | 2015-05-29 | Univ California | |
JPWO2015108047A1 (en) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | Chiral nucleic acid adjuvant having immunity induction activity and immunity induction activator |
WO2015108048A1 (en) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | Chiral nucleic acid adjuvant having antitumor effect and antitumor agent |
EP3095460A4 (en) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
PL3094728T3 (en) | 2014-01-16 | 2022-07-04 | Wave Life Sciences Ltd. | Chiral design |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4547569A (en) * | 1982-11-24 | 1985-10-15 | The United States Of America As Represented By The Department Of Health And Human Services | Intercalating agents specifying nucleotides |
US4958013A (en) * | 1989-06-06 | 1990-09-18 | Northwestern University | Cholesteryl modified oligonucleotides |
EP0652890B1 (en) * | 1992-07-27 | 1998-01-14 | HYBRIDON, Inc. | Oligonucleotide alkylphosphonothioates |
FR2705099B1 (en) * | 1993-05-12 | 1995-08-04 | Centre Nat Rech Scient | Phosphorothioate triester oligonucleotides and process for their preparation. |
ATE202569T1 (en) * | 1994-09-07 | 2001-07-15 | Hybridon Inc | PRODRUG OLIGONUCLEOTIDES |
AU5319396A (en) * | 1995-03-23 | 1996-10-08 | Hybridon, Inc. | Thiono triester modified antisense oligodeoxynucleotide phosphorothioates |
-
1997
- 1997-08-21 AU AU41561/97A patent/AU4156197A/en not_active Abandoned
- 1997-08-21 WO PCT/US1997/014751 patent/WO1998007734A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO1998007734A1 (en) | 1998-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2360195A (en) | Oligonucleotide repeat arrays | |
AU1623299A (en) | Nucleotide-based prodrugs | |
AU4040197A (en) | Microturbomachinery | |
AU3387997A (en) | Autonotification | |
AU4156197A (en) | Oligonucleotide prodrugs | |
AU4013397A (en) | Arylalkanoylpyridazines | |
AU4176997A (en) | 3-alkyl-3-phenyl-piperidines | |
AU2684197A (en) | Handleset | |
AU5259498A (en) | Antisense oligonucleotides | |
AU4218597A (en) | Superseat | |
AU3340797A (en) | Modified oligonucleotides | |
AU2786295A (en) | Spacing member | |
AU7918398A (en) | Oligonucleotide derivatives | |
AU2090897A (en) | Hydroxyhexahydropyridazines | |
AU5697699A (en) | Oligonucleotide protecting groups | |
AU1907095A (en) | Spacing member | |
AU3130597A (en) | Tristetraprolin | |
AU5310500A (en) | Pseudomycin prodrugs | |
AU3782797A (en) | Printer | |
AU2237197A (en) | Fishing-lure | |
AU4332497A (en) | Endo-beta-galactosidase | |
AU1900097A (en) | Cremators | |
AUPO894297A0 (en) | A distribution system | |
AU1597197A (en) | Thienoquinolines | |
AU3557397A (en) | Double-tau-profile |